Notably, oncogenic KrasG12D also elevates IL‐33 expression in PDA cells, thereby recruiting and activating TH2 and lymphoid cells 2, which in turn can provoke tumor growth through the secretion of protumorigenic cytokines, such as IL‐4, IL‐5, and IL‐13 [10]. This evidence concerns the gene IL33 and neoplasm.